Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patie
Therapeutic antibodies that block the programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) pathway have revolutionized immuno-oncology by inducing robust and durable responses in patients with various cancer including advanced non-small-cell lung cancer (NSCLC). However, these responses only occur in a subset of
| Condition(s) | Advanced Non Small Cell Lung Cancer |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Therapeutic antibodies that block the programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) pathway have revolutionized immuno-oncology by inducing robust and durable responses in patients with various cancer including advanced non-small-cell lung cancer (NSCLC). However, these responses only occur in a subset of patients, even in case of PD-L1 overexpression. Elucidating the determinants of response and resistance but also of severe immune-mediated adverse events is key to improving outcomes and developing new treatment strategies. Biomarkers that predict immune checkpoint inhibitors efficacy and toxicity are urgently needed and could emerge from characterization of tumor microenvironment. The purpose of PREDICTION project is to elucidate response and toxicity predictive immunopheno |
| Who can participate | Inclusion Criteria: * Adult patients * Advanced NSCLC with PD-L1 TPS of 50% or greater * Administration of first line pembrolizumab between January 2017 \& December 2019 Exclusion Criteria: * Auto-immune disease * Prior exposure to immunotherapy * First dose pembrolizumab administered after December 2019 |
| Sex | All |
| Lead sponsor | University Hospital, Brest |
| Locations | Brest, France |
| Start date | 2021-04-16 |
| NCT ID | NCT04886401 |
| Official listing | https://clinicaltrials.gov/study/NCT04886401 |